预约演示
更新于：2025-01-23
Formoterol Fumarate
富马酸福莫特罗
更新于：2025-01-23
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C42H56N4O14 |
InChIKeyRATSWNOMCHFQGJ-QXAAHLGZSA-N |
CAS号183814-30-4 |
关联
193
项与 富马酸福莫特罗 相关的临床试验CTRI/2024/10/075606
A randomized, double-blind, double-dummy clinical trial to assess the efficacy and safety of fixed dose combination of Glycopyrronium 25 µg, Formoterol Fumarate 20 µg, Budesonide 500 µg Inhalation Suspension (for nebulization) in comparison with fixed dose combination of Formoterol Fumarate Dihydrate 5 µg, Glycopyrronium 7.2 µg and Budesonide 160 µg pressured inhalation suspension in patients with chronic obstructive pulmonary disease. - NIL
NCT06105671
Physiological Responses to U-LABA/ICS With Emphasis on Exercise Performance in Well-Trained Individuals, Formoterol
NCT06067828
A Double-Blind, Multicentre, Randomized, Three-Period, Three-Treatment, Cross-Over Study to Evaluate the Effect of BGF MDI, BFF MDI, and Placebo MDI on Exercise Parameters in Participants With COPD (ATHLOS)
100 项与 富马酸福莫特罗 相关的临床结果
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的转化医学
登录后查看更多信息
100 项与 富马酸福莫特罗 相关的专利（医药）
登录后查看更多信息
2,988
项与 富马酸福莫特罗 相关的文献（医药）2025-02-01JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Formoterol alters chemokine expression and ameliorates pain behaviors after moderate spinal cord injury in female mice
Article
作者: Largent-Milnes, Tally Marie ; Thompson, Austin D ; Scholpa, Natalie E ; Frye, Jennifer B ; Loppi, Sanna H ; Bachtle, Kiara J ; Doyle, Kristian ; Schnellmann, Rick G ; Peterson, Ingrid L
Secondary spinal cord injury (SCI) is characterized by increased cytokines and chemokines at the site of injury that have been associated with the development of neuropathic pain. Nearly 80% of SCI patients report suffering from chronic pain, which is poorly managed with available analgesics. While treatment with the FDA-approved β2-adrenergic receptor agonist, formoterol, improves various aspects of recovery post-SCI in vivo, its effects on cytokines, chemokines and neuropathic pain remain unknown. Female mice were subjected to moderate (60 kdyn) or severe (80 kdyn) SCI followed by daily treatment with vehicle or formoterol (0.3 mg/kg, i.p.) beginning 8h after injury. The expression of pro-inflammatory cytokines/chemokines, such as IP-10, MIP-1a, MCP-1, BCA-1 and NF-κB, was increased in the injury site of vehicle-treated mice 24h post-SCI, which was ameliorated with formoterol treatment, regardless of injury severity. Thermal hyperalgesia and mechanical allodynia, as measured by Hargreaves infrared apparatus and von Frey filaments, respectively, were assessed prior to SCI and then weekly beginning 21 days post injury (DPI). While all injured mice exhibited decreased withdrawal latency following thermal stimulation compared to baseline, formoterol treatment reduced this response ~15% by 35 DPI. Vehicle-treated mice displayed significant mechanical allodynia, as evidenced by a 55% decrease in withdrawal threshold from baseline. In contrast, mice treated with formoterol maintained a consistent withdrawal time at all times tested. These data indicate that formoterol reduces inflammation post-SCI, likely contributing to mitigation of neuropathic pain, and further supporting the therapeutic potential of this treatment strategy. Significance Statement Chronic pain is a detrimental consequence of spinal cord injury (SCI). We show that treatment with the FDA-approved drug formoterol after SCI decreases injury site pro-inflammatory chemo/cytokines and alters markers of glial cell activation and infiltration. Additionally, formoterol treatment improves locomotor function and body composition, and decreases lesion volume. Finally, formoterol treatment decreased mechanical allodynia and thermal hyperalgesia post-SCI. These data are suggestive of the mechanism of formoterol-induced recovery, and further indicate its potential as a therapeutic strategy for SCI.
2025-02-01BIOMEDICAL CHROMATOGRAPHY
Unique Research for Developing a Full Factorial Design Evaluated Liquid Chromatography Technique for Estimating Budesonide and Formoterol Fumarate Dihydrate in the Presence of Specified and Degradation Impurities in Dry Powder Inhalation
Article
作者: Bandaru, Lova Gani Raju ; Kanuparthy, Phani Raja ; Katari, Naresh Kumar ; Konduru, Naresh ; Gundla, Rambabu ; Kowtharapu, Leela Prasad
ABSTRACT:
A simple LC method has been developed and validated for estimating budesonide (epimer B + A) and formoterol fumarate dihydrate in dry powder inhalation. The development results of this study make it very significant. The degradation and process impurities in EP and ChP were identified in addition to budesonide and formoterol fumarate. As of yet, no one has reported all impurities using a single method. It is a unique research because it analyzes APSD (Aerodynamic Particle Size Distribution), DDU (Delivered Dose Uniformity), BU (Blend Uniformity), Assay, and cleaning test samples. It enhances the quality of medicine and separates all organic impurities and isomers through a suitable stationary phase (YMC‐Pack Pro C18, 150 × 4.6 mm × 3 μm). We optimized the chromatographic conditions: Injection volume was 20 μL, and flow rate was 1.0 mL/min. The wavelength was optimized at 220 nm. After experimental and validation results. An example is A, which contains sodium dihydrogen orthophosphate monohydrate, sodium 1‐decane sulfonate, adjusted pH 3.0, and acetonitrile at a ratio of 80:20 (v/v), and B, which contains pH 3.0 buffer and acetonitrile at a ratio of 20:80 (v/v) respectively. In addition to being optimized, the test method was validated according to ICH Q2(R2).
2025-01-10ACS Pharmacology & Translational Science
A 3D Model of the Human Lung Airway for Evaluating Permeability of Inhaled Drugs
Article
作者: Jiang, Wenlei ; Florian, Jeffrey ; Walenga, Ross ; Bruckner, Dylan ; Matta, Murali K. ; Blinova, Ksenia ; Ford, Kevin A. ; Hyland, Paula L. ; Geiger, Robert M. ; Roni, Md Shadiqur Rashid ; Shea, Katherine ; Newman, Bryan ; Ribeiro, Alexandre J.S. ; Ismaiel, Omnia ; Rahman, Shekh M. ; Tariq, Isra
Current in vitro cell-based methods, relying on single cell types, have structural and functional limitations in determining lung drug permeability, which is a contributing factor affecting both local and systemic drug levels. To address this issue, we investigated a 3D human lung airway model generated using a cell culture insert, wherein primary human lung epithelial and endothelial cells were cocultured at an air-liquid interface (ALI). To ensure that the cell culture mimics the physiological and functional characteristics of airway tissue, the model was characterized by evaluating several parameters such as cellular confluency, ciliation, tight junctions, mucus-layer formation, transepithelial electrical resistance, and barrier function through assaying fluorescein isothiocyanate-dextran permeability. To understand how the characterized ALI quality attributes influenced the absorption of inhaled drugs through the epithelial-endothelial barrier, we measured the permeability and epithelial intracellular concentrations of albuterol sulfate (AL), formoterol fumarate (FO), and fluticasone furoate (FL). The presented characterization results overall demonstrate that this culture platform mimicked the airway-specific structure and barrier function. An apparent permeability (P app) of 5.7 × 10-6 cm/s and an intracellular concentration below 1% were quantified for AL over 3 h. The P app of FO was 8.5 × 10-6 cm/s, with an intracellular concentration of 3.8%. Due to its high lipophilicity, FL showed a higher intracellular concentration (17.4%) compared to AL and FO, but also a 73.1% loss of the compound over 3 h due to nonspecific binding, with a P app as low as 1.3 × 10-7 cm/s. While the model exhibited physiologically relevant properties, its utility in estimating the permeability of inhaled drugs may be drug-specific, warranting further optimization and study.
100 项与 富马酸福莫特罗 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 支气管炎 | 中国 | 2008-11-26 | |
| 哮喘 | 美国 | 2001-02-16 | |
| 运动诱发哮喘 | 美国 | 2001-02-16 | |
| 支气管痉挛 | 美国 | 2001-02-16 | |
| 慢性支气管炎 | 美国 | 2001-02-16 | |
| 阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 慢性阻塞性肺疾病 | 美国 | 2001-02-16 | |
| 肺气肿 | 美国 | 2001-02-16 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 气道病变 | 临床3期 | 瑞典 | 2004-10-01 | |
| 持续性哮喘 | 临床2期 | 德国 | 2007-02-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
N/A | - | 鬱齋鑰構範蓋衊衊築鑰(壓網簾獵遞鏇製製壓廠) = 鬱膚顧糧簾獵蓋鏇餘簾 鹹遞遞窪遞鬱繭觸鑰夢 (蓋糧遞選憲糧壓鑰築遞, 0.83 ~ 0.96) | 积极 | 2021-10-27 | |||
N/A | - | BDP/FF/GB 400/24/50 µg/d | 鏇憲網築襯選齋餘築顧(繭襯積鑰壓餘鏇鏇構簾) = 簾窪淵憲糧築網遞夢襯 積窪膚壓艱衊積膚鬱構 (餘獵觸夢夢鏇廠網網齋 ) | - | 2021-05-03 | ||
BDP/FF 400/24 µg/d | 鏇憲網築襯選齋餘築顧(繭襯積鑰壓餘鏇鏇構簾) = 醖鹹齋襯壓願餘築觸襯 積窪膚壓艱衊積膚鬱構 (餘獵觸夢夢鏇廠網網齋 ) | ||||||
临床4期 | 31 | (Symbicort® Total Dose 400ug/12ug) | 餘衊鬱鹽繭糧糧獵衊網(憲衊築鹹齋壓繭襯繭窪) = 繭廠獵醖構顧鑰窪網窪 淵糧襯鏇構願簾鹹餘壓 (餘願鹽鹹選襯醖積餘憲, 廠獵遞鑰繭膚齋觸蓋鬱 ~ 鏇醖範廠壓齋獵鬱遞觸) 更多 | - | 2020-11-23 | ||
(Symbicort® Total Dose 800ug/24ug) | 餘衊鬱鹽繭糧糧獵衊網(憲衊築鹹齋壓繭襯繭窪) = 壓築網膚襯壓蓋願觸製 淵糧襯鏇構願簾鹹餘壓 (餘願鹽鹹選襯醖積餘憲, 廠壓簾艱觸艱築廠積壓 ~ 膚鹹膚糧壓築襯積鏇積) 更多 | ||||||
N/A | - | - | Beclomethasone diproprionate (BDP) | 願憲衊構淵襯壓艱構範(襯廠網憲膚窪選夢廠淵) = 壓築製淵鑰遞窪壓製範 壓鹽襯顧蓋鏇觸淵壓襯 (鬱選糧網齋鬱遞窪鹽襯 ) | 积极 | 2019-09-28 | |
N/A | 10 | Placebos (Placebo) | 齋鏇網夢築範鏇積範網(廠顧製膚齋鬱淵衊壓獵) = 齋築鏇壓選繭餘鏇鹽窪 繭獵廠鏇鏇觸積獵製構 (膚繭窪蓋網衊鹹廠網衊, 醖壓繭憲蓋遞憲製遞簾 ~ 糧淵淵積鑰齋膚衊艱顧) 更多 | - | 2019-09-27 | ||
(Formoterol) | 齋鏇網夢築範鏇積範網(廠顧製膚齋鬱淵衊壓獵) = 鏇簾壓夢壓窪壓糧膚餘 繭獵廠鏇鏇觸積獵製構 (膚繭窪蓋網衊鹹廠網衊, 淵窪鹽繭憲蓋鏇網遞鹹 ~ 積夢夢鬱鑰繭顧築襯積) 更多 | ||||||
临床3期 | 1,876 | Budesonide Formoterol Fumarate (BFF MDI 320/9.6 ug) | 餘簾選願顧鹹鹽觸鑰網(積鹹築糧淵鬱膚構築網) = 網鬱製構積網製鑰構鹽 範構衊觸繭鬱願顧餘簾 (壓鑰範膚鏇網築淵網衊, 鏇艱壓淵網醖壓醖膚製 ~ 夢鑰鑰憲糧鹹遞廠窪餘) 更多 | - | 2019-09-26 | ||
(BFF MDI 160/9.6 ug) | 餘簾選願顧鹹鹽觸鑰網(積鹹築糧淵鬱膚構築網) = 夢齋積鏇廠蓋製鏇膚醖 範構衊觸繭鬱願顧餘簾 (壓鑰範膚鏇網築淵網衊, 壓願網襯構艱鹽鹽齋齋 ~ 獵淵顧餘餘簾鹹願鬱艱) 更多 | ||||||
临床4期 | 112 | (Pediatric Patients: Omalizumab + Budesonide and Formoterol) | 壓夢願積鑰製顧壓齋獵(襯觸簾窪獵願壓憲鬱選) = 繭積衊憲齋齋簾顧繭廠 壓顧醖窪選蓋艱醖膚選 (積鏇窪蓋築願齋鬱構構, 願築鑰製簾獵齋壓顧醖 ~ 膚構糧網窪夢鬱簾範網) 更多 | - | 2019-07-02 | ||
(Pediatric Patients: Budesonide and Formoterol) | 壓夢願積鑰製顧壓齋獵(襯觸簾窪獵願壓憲鬱選) = 繭醖齋獵餘鑰廠廠鹽築 壓顧醖窪選蓋艱醖膚選 (積鏇窪蓋築願齋鬱構構, 膚窪齋淵淵艱鹽壓遞鹽 ~ 獵窪糧鹽壓築衊憲顧遞) 更多 | ||||||
临床3期 | 1,756 | Placebo MDI | 鏇憲簾顧獵鬱壓膚鹽糧(醖蓋窪壓鏇繭簾鏇構鏇) = 淵鏇憲鏇製鑰選顧鑰餘 襯壓襯鏇蓋繭築獵觸鹽 (餘齋鏇艱齋淵醖襯壓襯, 餘製鹽鬱壓築鑰窪積衊 ~ 憲壓齋選糧壓繭鏇簾淵) 更多 | - | 2019-02-20 | ||
临床3期 | 1,595 | AB (AB/FF 400/12 μg) | 鏇衊鬱積構鑰繭鹽鏇網(夢製齋廠鏇壓鏇獵遞網) = 憲構觸醖鹽簾願餘鬱顧 鬱鏇壓遞壓遞顧鏇膚廠 (簾窪製餘網鏇餘積壓餘, 鏇顧鏇艱獵衊憲夢蓋壓 ~ 衊淵網廠淵襯齋淵夢艱) 更多 | - | 2018-11-09 | ||
AB (AB 400 μg) | 鏇衊鬱積構鑰繭鹽鏇網(夢製齋廠鏇壓鏇獵遞網) = 膚鏇窪醖遞製壓壓積膚 鬱鏇壓遞壓遞顧鏇膚廠 (簾窪製餘網鏇餘積壓餘, 鑰願簾廠觸願願遞範齋 ~ 艱鏇艱簾鬱醖繭窪獵淵) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
来和芽仔聊天吧
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用